FDA approved drugs:
| # |
|
Drug Name |
Active Ingredient(s) 18
|
Company |
Approval Date |
| 1 |
|
GastroMARK
18
|
FERUMOXSIL |
Advanced Magnetics |
May 1996 |
Disease/s that Drug Treats:gastrointestinal forms of cancer
Indications and Usage:
18
DrugBank Targets:
-
Mechanism of Action:
18
Target: -
Action: -
FDA: -
|
| 2 |
|
Gleevec
18
49
|
IMATINIB MESYLATE |
Novartis |
May 2001 |
Disease/s that Drug Treats:chronic myeloid leukemia/Gastrointestinal stromal tumors (GISTs)
Indications and Usage:
18
Gleevec⢠(imatinib mesylate) is indicated for the treatment of newly diagnosed adultpatients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronicphase. Follow-up is limited. Page 10Gleevec is also indicated for the treatment of patients with Philadelphia chromosomepositive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronicphase after failure of interferon-alpha therapy. Gleevec is also indicated for the treatment ofpediatric patients with Ph+ chronic phase CML whose disease has recurred after stem celltransplant or who are resistant to interferon alpha therapy. There are no controlled trialsdemonstrating a clinical benefit, such as improvement in disease-related symptoms orincreased survival.Gleevec is also indicated for the treatment of patients with Kit (CD117) positiveunresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). (SeeCLINICAL STUDIES: Gastrointestinal Stromal Tumors.) The effectiveness of Gleevec inGIST is based on objective response rate (see CLINICAL STUDIES). There are no controlledtrials demonstrating a clinical benefit, such as improvement in disease-related symptoms orincreased survival.
DrugBank Targets:
16
1. BCR/ABL fusion protein isoform X9;2. Mast/stem cell growth factor receptor Kit;3. RET proto-oncogene;4. High affinity nerve growth factor receptor;5. Macrophage colony-stimulating factor 1 receptor;6. Platelet-derived growth factor receptor alpha;7. Epithelial discoidin domain-containing receptor 1;8. Tyrosine-protein kinase ABL1;9. Platelet-derived growth factor receptor beta
Mechanism of Action:
18
Target: protein-tyrosine kinase
Action: inhibitor
FDA: Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosinekinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosomeabnormality in chronic myeloid leukemia (CML). It inhibits proliferation and inducesapoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphiachromosome positive chronic myeloid leukemia. In colony formation assays using ex vivoperipheral blood and bone marrow samples, imatinib shows inhibition of Bcr-Abl positivecolonies from CML patients.In vivo, it inhibits tumor growth of Bcr-Abl transfected murine myeloid cells as wellas Bcr-Abl positive leukemia lines derived from CML patients in blast crisis.Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derivedgrowth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF- andSCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis ingastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.
|
| 3 |
|
SecreFlo
18
|
SECRETIN SECRETIN SYNTHETIC PORCINE |
Repligen |
April 2002 |
Disease/s that Drug Treats:Pancreatic dysfunction and gastrinoma
Indications and Usage:
18
SecreFlo is indicated for use in secretin stimulation testing for: (1) Stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction, (2) Stimulation of gastrin secretion to aid in the diagnosis of gastrinoma.
DrugBank Targets:
16
1. Secretin receptor
Mechanism of Action:
18
Target: secreted pancreatic juices
Action: increase volume and bicarbonate content
FDA: The primary action of SecreFlo is to increase the volume and bicarbonate content ofsecreted pancreatic juices. The standard unit of activity used for SecreFlo is the clinicalunit defined by Jorpes & Mutt in 1966. (1) In the validated cat bioassay, which was usedto define and quantitate the biological activity of secretin and as the release test for thebiologically derived porcine secretin product, SecreFlo demonstrates a potency ofapproximately 5000 clinical units (CU) per milligram of peptide as opposed to 3000 CUper mg for biologically derived porcine secretin. As a pure peptide drug product,SecreFlo⢠dosing is expressed by weight in micrograms. The relationship ofmicrograms of secretin to biological activity is 0.2 mcg = 1 CU.
|
| 4 |
|
Stivarga
18
49
|
REGORAFENIB |
Bayer/ Bayer HealthCare Pharmaceuticals |
February 2013/ September 2012 |
Disease/s that Drug Treats:gastrointestinal stromal tumor/ metastatic colorectal cancer
Indications and Usage:
18
Stivarga is a kinase inhibitor indicated for the treatment of patients with: Metastatic colorectal cancer (CRC) who have been previously treated withfluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an antiVEGFtherapy, and, if KRAS wild type, an anti-EGFR therapy. (1.1) Locally advanced, unresectable or metastatic gastrointestinal stromal tumor(GIST) who have been previously treated with imatinib mesylate andsunitinib malate. (1.2)
DrugBank Targets:
16
1. Proto-oncogene tyrosine-protein kinase receptor Ret;2. Vascular endothelial growth factor receptor 1;3. Vascular endothelial growth factor receptor 2;4. Vascular endothelial growth factor receptor 3;5. Mast/stem cell growth factor receptor Kit;6. Platelet-derived growth factor receptor alpha;7. Platelet-derived growth factor receptor beta;8. Fibroblast growth factor receptor 1;9. Fibroblast growth factor receptor 2;10. Angiopoietin-1 receptor;11. Discoidin domain-containing receptor 2;12. High affinity nerve growth factor receptor;13. Ephrin type-A receptor 2;14. RAF proto-oncogene serine/threonine-protein kinase;15. Serine/threonine-protein kinase B-raf;16. Mitogen-activated protein kinase 11;17. Tyrosine-protein kinase FRK;18. Tyrosine-protein kinase ABL1
Mechanism of Action:
18
Target: RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2,TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E , SAPK2, PTK5, and Abl kinases
Action: inhibitor
FDA: Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normalcellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumormicroenvironment. In in vitro biochemical or cellular assays, regorafenib or its major human active metabolites M-2 andM-5 inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2,TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E , SAPK2, PTK5, and Abl at concentrations of regorafenib thathave been achieved clinically. In in vivo models, regorafenib demonstrated anti-angiogenic activity in a rat tumor model,and inhibition of tumor growth as well as anti-metastatic activity in several mouse xenograft models including some forhuman colorectal carcinoma.
|
| 5 |
|
Sutent
18
49
|
SUNITINIB MALATE |
Pfizer |
May 2011/ January 2006 |
Disease/s that Drug Treats:pancreatic neuroendocrine tumors/ Kidney Cancer/Gastrointestinal Stromal Tumors
Indications and Usage:
18
SUTENT is a kinase inhibitor indicated for the treatment of: Gastrointestinal stromal tumor (GIST) after disease progression on orintolerance to imatinib mesylate. (1.1) Advanced renal cell carcinoma (RCC). (1.2) Progressive, well-differentiated pancreatic neuroendocrine tumors(pNET) in patients with unresectable locally advanced or metastaticdisease. (1.3)
DrugBank Targets:
16
1. Platelet-derived growth factor receptor beta;2. Vascular endothelial growth factor receptor 1;3. Mast/stem cell growth factor receptor Kit;4. Vascular endothelial growth factor receptor 2;5. Vascular endothelial growth factor receptor 3;6. Receptor-type tyrosine-protein kinase FLT3;7. Macrophage colony-stimulating factor 1 receptor;8. Platelet-derived growth factor receptor alpha
Mechanism of Action:
18
Target: variety of kinases, platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET)
Action: inhibitor
FDA: Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which areimplicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib wasevaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitorof platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical andcellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primarymetabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRï¢, VEGFR2, KIT) in tumor xenograftsexpressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/orinhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibitgrowth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibitPDGFRï¢- and VEGFR2-dependent tumor angiogenesis in vivo.
|
Drugs for Gastrointestinal System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 308)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Oxaliplatin |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
61825-94-3 |
5310940
9887054
43805
6857599
|
|
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
Oxalatoplatinum
|
oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
|
|
| 2 |
|
Celecoxib |
Approved, Investigational |
Phase 4,Phase 1 |
|
169590-42-5 |
2662
|
|
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC1L1E6K
AC-4228
AI-525
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
celecoxib
Celecoxib
Célécoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
cMAP_000027
CPD000550473
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
|
KBio2_000912
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
Medicoxib
MLS001165684
MLS001195656
MLS001304708
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulphonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC58635
SC-58635
SMR000550473
Solexa
SPBio_001512
Spectrum_000432
SPECTRUM1503678
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM177
YM-177
ZINC02570895
|
|
| 3 |
|
Parecoxib |
Approved |
Phase 4 |
|
198470-84-7 |
|
| 4 |
|
Tramadol |
Approved, Investigational |
Phase 4 |
|
27203-92-5 |
33741
|
|
Synonyms:
(+)-(R,R)-trans-Tramadol
(+)-Tramadol
(+)-trans-2-(Dimethylaminomethyl)-1-(m-methoxyphenyl)cyclohexanol
(+)-trans-Tramadol free ba
(1R,2R)-2-(dimethylaminomethyl)-1-(3-methoxyphenyl)cyclohexan-1-ol
(1R,2R)-2-[(dimethylamino)methyl]-1-[3-(methyloxy)phenyl]cyclohexanol
(1R,2R)-2-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexanol
1a Brand OF tramadol hydrochloride
27203-92-5
AbZ brand OF tramadol hydrochloride
AC1L1Q6E
AC1Q59O2
Acis brand OF tramadol hydrochloride
Adolonta
AKOS005066335
Aliud brand OF tramadol hydrochloride
Allphar brand OF tramadol hydrochloride
Alpharma brand OF tramadol hydrochloride
Amadol
Amanda
Amanda (TN)
Antigen brand OF tramadol hydrochloride
ASTA medica brand OF tramadol hydrochloride
Azupharma brand OF tramadol hydrochloride
Basics brand OF tramadol hydrochloride
Bayvit brand OF tramadol hydrochloride
Betapharm brand OF tramadol hydrochloride
Bexal brand OF tramadol hydrochloride
BIDD:GT0075
Biocodex brand OF tramadol hydrochloride
Biodalgic
Biokanol
Byk brand OF tramadol hydrochloride
C07153
CHEMBL1066
Christiaens brand OF tramadol hydrochloride
Ciclum brand OF tramadol hydrochloride
CID33741
Cinfa brand OF tramadol hydrochloride
Clonmel brand OF tramadol hydrochloride
Contramal
Crispin
CSL Brand OF tramadol hydrochloride
D08623
DB00193
Docpharm brand OF tramadol hydrochloride
Dolorgiet brand OF tramadol hydrochloride
Edigen brand OF tramadol hydrochloride
EINECS 248-319-6
Elerte brand OF tramadol hydrochloride
Erempharma brand OF tramadol hydrochloride
Expanscience brand OF tramadol hydrochloride
Grunenthal brand OF tramadol hydrochloride
Hameln brand OF tramadol hydrochloride
Heumann brand OF tramadol hydrochloride
Hexal brand OF tramadol hydrochloride
HMS2090D10
Janssen brand OF tramadol hydrochloride
Jsp005295
Juta brand OF tramadol hydrochloride
Jutadol
Kade brand OF tramadol hydrochloride
Kern brand OF tramadol hydrochloride
Knoll brand OF tramadol hydrochloride
Krewel brand OF tramadol hydrochloride
Lakeside brand OF tramadol hydrochloride
Lichtenstein brand OF tramadol hydrochloride
Lindopharm brand OF tramadol hydrochloride
LS-57115
LS-57116
mabo Brand OF tramadol hydrochloride
Medix brand OF tramadol hydrochloride
Merck dura brand OF tramadol hydrochloride
MLS000333190
MolPort-002-507-778
MTW Brand OF tramadol hydrochloride
MTW Tramadol
MTWTramadol
MTW-Tramadol
Mundipharma brand OF tramadol hydrochloride
NCGC00159343-02
Nobligan
Normon brand OF tramadol hydrochloride
ortho Brand OF tramadol hydrochloride
Prontofort
Q Pharm brand OF tramadol hydrochloride
Q-Pharm brand OF tramadol hydrochloride
Ralivia ER
|
Ralivia flashtab
Ralivia Flashtab
Ranitidin 1a pharma
Ratiopharm brand OF tramadol hydrochloride
Rowa brand OF tramadol hydrochloride
Searle brand OF tramadol hydrochloride
SMR000436547
Stadapharm brand OF tramadol hydrochloride
STOCK4S-19075
TAD brand OF tramadol hydrochloride
Takadol
Theradol
Theraplix brand OF tramadol hydrochloride
Tiral
Topalgic
Tradol
Tradol puren
Tradol-puren
TradolPuren
Tradonal
Tradonal odis
Tralgiol
Trama 1a pharma
Trama abz
Trama dorsch
Trama KD
Tramabeta
Tramadin
Tramadoc
tramadol
Tramadol
Tramadol (INN)
Tramadol [INN:BAN]
Tramadol 1a
Tramadol acis
Tramadol al
Tramadol asta medica
Tramadol basics
Tramadol bayvit
Tramadol bexal
Tramadol cinfa
Tramadol dolgit
Tramadol edigen
Tramadol hameln
Tramadol HCl
Tramadol HCl BP/EP
Tramadol heumann
Tramadol hydrochloride
Tramadol kern
Tramadol lichtenstein
Tramadol lindo
Tramadol mabo
Tramadol normon
Tramadol PB
Tramadol ratiopharm
Tramadol stada
Tramadol viatris brand
Tramadol-dolgit
TramadolDolgit
Tramadol-hameln
TramadolHameln
Tramadolor
Tramadolratiopharm
Tramadol-ratiopharm
Tramadolum
Tramadolum [INN-Latin]
Trama-dorsch
TramaDorsch
Tramadura
Tramagetic
Tramagit
Tramake
Tramal
Tramex
Tramodol Hcl
Tramundin
Trasedal
Tridural
Ultram
Ultram ER
UNII-39J1LGJ30J
Viatris brand OF tramadol
Xymel 50
Zambon brand OF tramadol hydrochloride
Zamudol
Zumalgic
Zydol
Zytram
|
|
| 5 |
|
Fluorouracil |
Approved |
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable |
|
51-21-8 |
3385
|
|
Synonyms:
1004-03-1
1-fluoro-1h-pyrimidine-2,4-dione
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 Fluorouracil
5 Fluorouracil biosyn
5 FU lederle
5 FU Lederle
5 FU medac
5 HU hexal
5 HU Hexal
51-21-8
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-fluoropyrimidine-2,4(1H,3H)-dione
5-Fluoropyrimidine-2,4-dione
5-fluorouracil
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5FU
5-FU
5-FU (TN)
5-FU lederle
5-FU Lederle
5-FU medac
5-HU hexal
5-HU Hexal
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
AI3-25297
AKOS000119162
AKOS003237897
Allergan brand OF fluorouracil
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
biosyn Brand of Fluorouracil
Biosyn brand OF fluorouracil
BSPBio_002048
C07649
C4H3FN2O2
Carac
Carac (TN)
Carzonal
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
Cinco FU
CPD000038082
CPD0-1327
CSP Brand of Fluorouracil
CSP Brand OF fluorouracil
Cytosafe
D005472
D00584
Dakota brand OF fluorouracil
Dakota Brand of Fluorouracil
Dakota, fluorouracile
Dakota, Fluorouracile
DB00544
Dermatech brand OF fluorouracil
Dermatech Brand of Fluorouracil
Dermik brand OF fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
EINECS 200-085-6
EU-0100536
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
Ferrer brand OF fluorouracil
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
fluoro Uracile icn
Fluoro Uracile ICN
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
fluorouracil
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil [USAN:INN:BAN:JAN]
Fluorouracil gry
Fluorouracil GRY
Fluorouracil mononitrate
Fluorouracil Mononitrate
Fluorouracil monopotassium salt
Fluorouracil Monopotassium Salt
Fluorouracil monosodium salt
Fluorouracil Monosodium Salt
Fluorouracil potassium salt
Fluorouracil Potassium Salt
Fluorouracil teva brand
Fluorouracil Teva Brand
Fluorouracile
Fluoro-uracile
Fluorouracile [DCIT]
|
Fluorouracile dakota
Fluorouracile Dakota
fluoro-Uracile icn
Fluoro-Uracile ICN
Fluorouracil-gry
Fluorouracil-GRY
Fluorouracilo
Fluoro-uracilo
Fluorouracilo [INN-Spanish]
fluorouracilo Ferrer far
Fluorouracilo Ferrer Far
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
FT-0082524
Ftoruracil
FU
Gry brand OF fluorouracil
Gry Brand of Fluorouracil
haemato Brand OF fluorouracil
Haemato Brand of Fluorouracil
haemato Fu
Haemato fu
haemato-Fu
Haemato-fu
Hexal brand OF fluorouracil
Hexal Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
I07-0022
ICN brand OF fluorouracil
ICN Brand of Fluorouracil
IDI1_000054
IN1335
inhibits thymilidate synthetase
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
Lopac0_000536
Lopac-F-6627
LS-153
medac Brand of Fluorouracil
Medac brand OF fluorouracil
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
nchembio.90-comp3
nchembio809-comp6
NCI60_001652
Neocorp brand OF fluorouracil
Neocorp Brand of Fluorouracil
Neofluor
NINDS_000054
NSC 19893
NSC19893
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Onkoworks Brand of Fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
ribosepharm Brand of Fluorouracil
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche brand OF fluorouracil
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
Spectrum_000841
SPECTRUM1500305
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
STK297802
T5233394
tetratogen
Teva brand OF fluorouracil
Teva Brand of Fluorouracil
Timazin
TL8006093
U 8953
U-8953
Ulup
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
WLN: T6MVMVJ EF
ZINC00897110
|
|
| 6 |
|
Rocuronium |
Approved |
Phase 4 |
|
119302-91-9, 143558-00-3 |
441290
|
|
Synonyms:
(2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
1-(17-(Acetoyl)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)pyrrolidinium
143558-00-3
AC1L9AWM
BIDD:GT0360
C07556
CHEBI:8884
CID441290
|
DB00728
Esmeron
Esmerone
HMS2090E03
NCGC00167433-01
Pyrrolidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)-, bromide
Rocuronium
Rocuronium bromide
Zemuron
|
|
| 7 |
|
Insulin Glargine |
Approved |
Phase 4 |
|
160337-95-1 |
|
|
Synonyms:
Insulin Glargine (rDNA origin)
|
Insulin glargine recombinant
|
|
| 8 |
|
Zinc |
Approved, Investigational |
Phase 4 |
|
7440-66-6 |
23994
|
|
Synonyms:
30Zn
Cinc
Dietary zinc
Zinc
Zinc cation
ZINC ion
Zinc, ion (ZN2+)
Zincum
|
Zink
Zn
ZN(2+)
Zn(ii)
ZN(II)
Zn2+
ZN2+
|
|
| 9 |
|
Enoxaparin |
Approved |
Phase 4 |
|
9005-49-6 |
772
|
|
Synonyms:
2-o-sulfohexopyranuronosyl-(1->4)-2-deoxy-3-o-sulfo-2-(sulfoamino)hexopyranosyl-(1->4)-2-o-sulfohexopyranuronosyl-(1->4)-2-acetamido-2-deoxy-6-o-sulfohexopyranose
6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
AC1L19ZN
AR-1E4539
CID772
Clexane
D006495
D017984
DB00407
DB01225
EMT 966
EMT 967
EMT966
EMT-966
EMT967
EMT-967
|
enoxaparin
Enoxaparin sodium
Enoxaparine
Heparin, Low Molecular Weight
Heparin, Low-Molecular-Weight
LMWH
Lovenox
Lovenox HP
Low molecular weight heparin
Low molecular weight heparin sodium
Low-Molecular-Weight Heparin
PK 10,169
PK10,169
PK-10,169
PK10169
PK-10169
|
|
| 10 |
|
Amoxicillin |
Approved, Vet_approved |
Phase 4 |
|
26787-78-0 |
33613
|
|
Synonyms:
(-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid
(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
26787-78-0
33911-69-2
34642-77-8 (mono-hydrochloride salt)
4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D- (8CI)
6-(a-amino-4-hydroxyphenylacetamido)Penicillanic acid
6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid
6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin
6-(D-(-)-P-Hydroxy-alpha-aminobenzyl)penicillin
6-(P-Hydroxy-a-aminophenylacetamido)penicillanate
6-(P-Hydroxy-a-aminophenylacetamido)penicillanic acid
6-(P-Hydroxy-alpha-aminophenylacetamido)penicillanate
6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid
6-(P-Hydroxy-alpha-aminophenylacetamido)penicillanic acid
6-(P-Hydroxy-α-aminophenylacetamido)penicillanate
6-(p-hydroxy-α-aminophenylacetamido)penicillanic acid
6-(P-Hydroxy-α-aminophenylacetamido)penicillanic acid
6-[[amino(4-Hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 9ci
61336-70-7 (TRIHYDRATE)
6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carbonyl
6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
71447-36-4
81030-75-3
a-amino-P-Hydroxybenzylpenicillin
AC-12263
AC1L1PY2
Actimoxi
Almodan
alpha-amino-P-Hydroxybenzylpenicillin
alpha-Amino-p-hydroxybenzylpenicillin
Ambap26787-78-0
AMC
Amix
Amoclen
Amolin
Amopen
Amopenixin
Amoram
Amox
Amox 250 cap 250MG
Amox 500 cap 500MG
Amox S 125 sus 125mg/5ML
Amox S 250 sus 250mg/5ML
Amoxi
Amoxibiotic
Amoxicaps
Amoxicilina
Amoxicilina [INN-Spanish]
amoxicillanyl
amoxicillin
Amoxicillin
Amoxicillin (anhydrous)
Amoxicillin (INN)
Amoxicillin (TN)
Amoxicillin and clavulanate potassium
Amoxicillin anhydrous
Amoxicillin clariana brand
AMOXICILLIN CRYSTALLINE
Amoxicillin monopotassium salt
Amoxicillin monosodium salt
Amoxicillin pediatric
AMOXICILLIN PEDIATRIC
Amoxicillin sodium
Amoxicillin trihydrate
Amoxicillin Trihydrate
Amoxicillin(usan)
Amoxicillin, (r*)-isomer
Amoxicilline
Amoxicilline [INN]
Amoxicilline [INN-French]
Amoxicillinum
Amoxicillinum [INN-Latin]
Amoxid
Amoxiden
Amoxil
Amoxi-mast
Amoxi-Mast
Amoxivet
Amoxycilin
Amoxycillin
Amoxycillin trihydrate
Amoxycillin Trihydrate
Amoxycillin, ban
Amoxymed
AMPC
Amrit
Anemolin
Anhydrous, amoxicillin
apo-Amoxi
Apo-Amoxi
apo-Amoxi cap 250MG
apo-Amoxi cap 500MG
apo-Amoxi PWR for susp 125mg/5ML
apo-Amoxi PWR for susp 250mg/5ML
apo-Amoxi sugar free
Aspenil
AUGMENTIN '125'
AUGMENTIN '200'
AUGMENTIN '250'
AUGMENTIN '400'
AUGMENTIN '500'
AUGMENTIN '875'
AUGMENTIN es-600
AX
Biomox
BLP 1410
BL-P 1410
|
BPBio1_000499
BRD-K55044200-001-03-9
Bristamox
BRL 2333
BRL-2333
BSPBio_000453
C06827
Cemoxin
CHEBI:2676
CHEBI:53712
CHEMBL1082
CID33613
Clamoxyl
Clamoxyl (SKB)
Clamoxyl g.a.
Clamoxyl parenteral
Clariana brand OF amoxicillin
CPD000058707
D-(-)-alpha-amino-P-Hydroxybenzyl penicillin
D-(-)-alpha-amino-P-Hydroxybenzylpenicillin
D-(-)-alpha-Amino-p-hydroxybenzylpenicillin
D-(alpha-amino-P-Hydroxybenzyl)penicillin
D07452
D-2-amino-2-(4-Hydroxyphenyl)acetamidopenicillanic acid
D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid
D-Amoxicillin
DB01060
Delacillin
Dispermox
DisperMox
Efpenix
EINECS 248-003-8
Flemoxin
G.A., clamoxyl
Galenamox
Gen-amoxicillin 250MG
Gen-amoxicillin 500MG
Hiconcil
Histocillin
HMS1569G15
HSDB 3204
Hydroxyampicillin
Ibiamox
Imacillin
Lamoxy
Larotid
LS-149721
Metafarma capsules
Metifarma capsules
MLS000028632
MLS002222248
MolPort-003-981-182
MolPort-005-933-687
Moxacin
Moxal
Moxatag
NCGC00179554-01
Novamoxin cap 250MG
Novamoxin cap 500MG
Novamoxin sus 125mg/5ML
Novamoxin sus 250mg/5ML
NSC 277174
NSC277174
Nu-amoxi cap 250MG
Nu-amoxi cap 500MG
Nu-amoxi sus 125/5ML
Nu-amoxi sus 250mg/5ML
Ospamox
Pamoxicillin
Parenteral, clamoxyl
Penamox
Pfizer brand OF amoxicillin sodium salt
PHL-Amoxicillin
p-Hydroxyampicillin
P-Hydroxyampicillin
Piramox
PMS-Amoxicillin
Polymox
Prestwick_713
Prestwick0_000357
Prestwick1_000357
Prestwick2_000357
Prestwick3_000357
Prevpac
pro Amox PWR for oral susp 125mg/5ML
pro Amox-250 cap 250MG
pro Amox-500 cap 500MG
pro-Amox-250 orl sus 250mg/5ML
R-Hydroxyampicillin
Rimoxallin
Ro 10-8756
Robamox
SAM002264592
Sauracillin
Sawamox PM
SmithKline beecham brand OF amoxicillin sodium salt
SMR000058707
Sodium, amoxicillin
SPBio_002374
Sumox
Tolodina
Trihydrate, amoxicillin
Trimox
Unicillin
Utimox
Vetramox
Wymox
Zimox
α-amino-p-hydroxybenzylpenicillin
α-amino-P-hydroxybenzylpenicillin
|
|
| 11 |
|
Clarithromycin |
Approved |
Phase 4 |
|
81103-11-9 |
84029
|
|
Synonyms:
(14R)-14-Hydroxyclarithromycin
116836-41-0
6-O-methyl erythromycin
6-O-Methylerythromycin
6-O-Methylerythromycin a
81103-11-9
A-56268
Abbotic
Abbott-56268
AC1L1HJO
AC1L36NJ
AC1NFSZE
AC1NR4MY
AC1NSJWH
AC1O52DV
AC1Q6O1T
AC-6813
Adel
ANX-015
Astromen
BB_NC-1450
Biaxin
Biaxin (TN)
Biaxin filmtab
Biaxin HP
Biaxin XL
Biaxin xl filmtab
Bicrolid
BIDD:GT0200
Bio-0020
BSPBio_003453
C06912
C2220
C30H54O11.C9H19NO2
CCRIS 8833
CHEBI:136451
CHEBI:3732
CHEMBL143
CHEMBL1741
CID10147055
CID10328822
CID11814635
CID11828745
CID11969952
CID4663848
CID489010
CID5284534
CID5311050
CID54688
CID6426662
CID84029
CID9810688
CID9811194
CLA
Clacine
Clambiotic
Claribid
Claricide
Clarith
clarithromycin
CLARITHROMYCIN
Clarithromycin & Interleukin-12
Clarithromycin (JP15/USP/INN)
Clarithromycin [USAN:INN:BAN:JAN]
Clarithromycin extended release
Clarithromycin suspension or tablets
clarithromycina
Clarithromycina
Clarithromycine
Clarithromycine [INN-French]
Clarithromycinum
Clarithromycinum [INN-Latin]
Claritromicina
|
Claritromicina [INN-Spanish]
Clathromycin
CLM & IL-12
CPD000466382
CRL-1605 & Clarithromycin
CTY
Cyllid
Cyllind
D00276
DivK1c_006655
DRG-0099
Helas
Heliclar
HMS1922H09
HMS2051G18
HMS2090O11
HMS2094M05
hydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexame
I05-0074
KBio1_001599
KBio2_000509
KBio2_003077
KBio2_005645
KBio3_002673
KBioGR_001218
KBioSS_000509
Klacid
Klaciped
Klaricid
Klaricid H.P
Klaricid H.P.
Klaricid Pediatric
Klaricid XL
Klarid
Klarin
Klax
Kofron
Lactoferrin B & Clarithromycin
Lactoferrin H & Clarithromycin
LMPK04000014
LS-1812
Mabicrol
Macladin
Maclar
Mavid
MLS000759516
MLS001201751
MLS001424066
MolPort-002-507-425
MolPort-003-845-969
MolPort-005-910-192
MolPort-005-934-146
Naxy
NCGC00178054-01
NSC643733
O(6)-methylerythromycin
SAM001246748
SDP-015
SMR000466382
SPBio_001855
SpecPlus_000559
Spectrum_000089
SPECTRUM1504231
Spectrum2_001668
Spectrum3_001667
Spectrum4_000629
Spectrum5_001729
STK801952
TE031
TE-031
UNII-H1250JIK0A
Veclam
Zeclar
|
|
| 12 |
|
Rabeprazole |
Approved, Investigational |
Phase 4 |
|
117976-89-3 |
5029
|
|
Synonyms:
117976-89-3
1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, sodium salt
2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole
2-((4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole
2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole
2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole
AC1L1JGC
Aciphex
AcipHex
BIDD:GT0019
C063129
C07864
C18H21N3O3S
CHEBI:8768
CHEMBL1219
CID5029
CL23619
Clofezone
CPD000469174
D08463
DB01129
dexrabeprazole
Dexrabeprazole
Eraloc
|
Eraloc (TN)
Habeprazole
HMS2052P03
HSDB 7321
I06-0755
Irsogladine Maleate
LS-172365
LY307640
MLS001401446
MolPort-005-935-061
Pariet
Pariets
rabeprazole
Rabeprazole
Rabeprazole (INN)
Rabeprazole [BAN:INN]
Rabeprazole [INN:BAN]
rabeprazole sodium
Rabeprazole sodium
Rebeprazole sodium
SAM001246619
SMR000469174
Sodium rabeprazole
Sodium, rabeprazole
UNII-32828355LL
|
|
| 13 |
|
Liver Extracts |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 14 |
|
Analgesics |
|
Phase 4,Phase 3,Phase 1,Phase 2 |
|
|
|
| 15 |
|
Analgesics, Non-Narcotic |
|
Phase 4,Phase 3,Phase 1,Phase 2 |
|
|
|
| 16 |
|
Analgesics, Opioid |
|
Phase 4 |
|
|
|
| 17 |
|
Anti-Inflammatory Agents |
|
Phase 4,Phase 3,Phase 1,Not Applicable |
|
|
|
| 18 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4,Phase 3,Phase 1 |
|
|
|
| 19 |
|
Antirheumatic Agents |
|
Phase 4,Phase 3,Phase 1,Phase 2 |
|
|
|
| 20 |
|
Central Nervous System Depressants |
|
Phase 4,Phase 3 |
|
|
|
| 21 |
|
Cyclooxygenase 2 Inhibitors |
|
Phase 4,Phase 3,Phase 1 |
|
|
|
| 22 |
|
Cyclooxygenase Inhibitors |
|
Phase 4,Phase 3,Phase 1 |
|
|
|
| 23 |
|
insulin |
|
Phase 4 |
|
|
|
| 24 |
|
Insulin, Globin Zinc |
|
Phase 4 |
|
|
|
| 25 |
|
Narcotics |
|
Phase 4 |
|
|
|
| 26 |
|
Peripheral Nervous System Agents |
|
Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable |
|
|
|
| 27 |
|
Vitamins |
|
Phase 4,Phase 2,Phase 1,Not Applicable |
|
|
|
| 28 |
|
Pharmaceutical Solutions |
|
Phase 4,Phase 1,Phase 2,Not Applicable |
|
|
|
| 29 |
|
Anticoagulants |
|
Phase 4,Phase 1,Not Applicable |
|
|
|
| 30 |
|
Anti-Bacterial Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 31 |
|
Anti-Infective Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 32 |
|
Gastrointestinal Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 33 |
|
Protective Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
| 34 |
|
Neuromuscular Agents |
|
Phase 4 |
|
|
|
| 35 |
|
Neuromuscular Blocking Agents |
|
Phase 4 |
|
|
|
| 36 |
|
Neuromuscular Nondepolarizing Agents |
|
Phase 4 |
|
|
|
| 37 |
|
Hypoglycemic Agents |
|
Phase 4,Phase 1,Phase 2,Not Applicable |
|
|
|
| 38 |
|
Antacids |
|
Phase 4 |
|
|
|
| 39 |
|
Anti-Ulcer Agents |
|
Phase 4 |
|
|
|
| 40 |
|
Proton Pump Inhibitors |
|
Phase 4 |
|
|
|
| 41 |
|
Calcium, Dietary |
|
Phase 4,Phase 2,Phase 3,Phase 1 |
|
|
|
| 42 |
|
Vasodilator Agents |
|
Phase 4,Phase 1,Early Phase 1 |
|
|
|
| 43 |
|
Fibrinolytic Agents |
|
Phase 4,Not Applicable |
|
|
|
| 44 |
|
Cytochrome P-450 CYP3A Inhibitors |
|
Phase 4 |
|
|
|
| 45 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 4 |
|
|
|
| 46 |
|
HIV Protease Inhibitors |
|
Phase 4,Phase 1,Phase 2,Not Applicable |
|
|
|
| 47 |
|
protease inhibitors |
|
Phase 4,Phase 1,Phase 2,Not Applicable |
|
|
|
|
Synonyms:
|
| 48 |
|
Bufanolides |
|
Phase 4 |
|
|
|
| 49 |
|
Antihypertensive Agents |
|
Phase 4,Early Phase 1 |
|
|
|
| 50 |
|
Cola |
Nutraceutical |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 383)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer |
Unknown status |
NCT00274885
|
Phase 4 |
oxaliplatin |
| 2 |
Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery |
Unknown status |
NCT01930318
|
Phase 4 |
parecoxib |
| 3 |
Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery |
Unknown status |
NCT00790140
|
Phase 4 |
|
| 4 |
Nutritional Supplementation in Patients With no Signs of Malnutrition |
Unknown status |
NCT01894828
|
Phase 4 |
|
| 5 |
Medium Calorie Parenteral Nutrition on Patients With Gastrointestinal Cancer Undergoing Surgery |
Completed |
NCT01700062
|
Phase 4 |
|
| 6 |
The Laparotomy Study |
Completed |
NCT02140593
|
Phase 4 |
Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).;Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment. |
| 7 |
Glargine Insulin vs.Continuous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN) |
Completed |
NCT02216799
|
Phase 4 |
Glargine Insulin;Regular insulin |
| 8 |
Standard and Immunostimulating Enteral Nutrition in Surgical Patients |
Completed |
NCT00576940
|
Phase 4 |
Reconvan;Peptisorb |
| 9 |
The Impact of Immunostimulating Nutrition on the Outcome of Surgery |
Completed |
NCT00558155
|
Phase 4 |
peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven |
| 10 |
Comparison of Thromboembolic Events Between Enoxa® and Lovenox® in Patients Undergoing Digestive Cancer |
Recruiting |
NCT02444572
|
Phase 4 |
Enoxaparin 4000 UI |
| 11 |
10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication |
Recruiting |
NCT03134378
|
Phase 4 |
Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg |
| 12 |
Clinical Trial of Cinobufacini Injection Combined With Oxaliplatin Regimen on Gastrointestine Carcinoma |
Not yet recruiting |
NCT02860429
|
Phase 4 |
Cinobufacini injection;chemotherapy |
| 13 |
Aliskiren Study of Safety and Efficacy in Senior Hypertensives |
Withdrawn |
NCT01922141
|
Phase 4 |
Aliskiren;Amlodipine;Ramipril;Hydrochlorothiazide |
| 14 |
Genetically-informed Therapies for Patients With Metastatic Cancer |
Withdrawn |
NCT02000739
|
Phase 4 |
|
| 15 |
Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer |
Unknown status |
NCT00209742
|
Phase 3 |
UFT;USEL/Leucovorin;Krestin |
| 16 |
Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial |
Unknown status |
NCT00164892
|
Phase 3 |
Oral Vioxx (Rofecoxib) |
| 17 |
Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial |
Unknown status |
NCT00165048
|
Phase 3 |
Vioxx (Rofecoxib) |
| 18 |
Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers |
Unknown status |
NCT02161991
|
Phase 3 |
Aprepitant;placebo |
| 19 |
Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer |
Completed |
NCT02486198
|
Phase 3 |
placebo;GM;oxaliplatin-based chemotherapy |
| 20 |
Home Enteral Nutrition in Malnourished Patients With Gastrointestinal Cancer |
Completed |
NCT02664974
|
Phase 3 |
|
| 21 |
Immunonutrition and Quality of Life of Cancer Patients Undergoing Oncological Treatment |
Completed |
NCT01423799
|
Phase 3 |
|
| 22 |
Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting |
Completed |
NCT00971399
|
Phase 3 |
ramosetron;ondansetron |
| 23 |
Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery |
Completed |
NCT00798447
|
Phase 3 |
MLF 541;Lipofundin MCT |
| 24 |
Efficacy of an Oral Formula in Prevention of Anti-cancer Therapy Side Effects |
Completed |
NCT00455247
|
Phase 3 |
Glutamine |
| 25 |
Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients |
Completed |
NCT00513357
|
Phase 3 |
Melatonin;Placebo |
| 26 |
Prevention of Oxaliplatin-induced Neuropathic Pain by a Specific Diet |
Completed |
NCT01775449
|
Phase 3 |
|
| 27 |
Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma |
Completed |
NCT01829178
|
Phase 2, Phase 3 |
Silymarin;Placebo;chemotherapy |
| 28 |
Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis |
Completed |
NCT00052962
|
Phase 3 |
|
| 29 |
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer |
Completed |
NCT01360853
|
Phase 3 |
ON 01910.Na;Gemcitabine;Gemcitabine |
| 30 |
Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients |
Completed |
NCT01523431
|
Phase 2, Phase 3 |
Irinotecan Injection [Camptosar];5-fluorouracil;Leucovorin |
| 31 |
Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy |
Recruiting |
NCT02853474
|
Phase 3 |
|
| 32 |
Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive Cancer |
Recruiting |
NCT02956876
|
Phase 3 |
standard chemotherapy for colorectal cancer |
| 33 |
Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours |
Recruiting |
NCT02591030
|
Phase 2, Phase 3 |
GEMCIS;mFolfirinox |
| 34 |
SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients |
Recruiting |
NCT03448549
|
Phase 3 |
Oxaliplatin;Tegafur，gimeracil and oteracil potassium;Xeloda |
| 35 |
Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1) |
Recruiting |
NCT03199989
|
Phase 3 |
CapeOX（Capecitabine+Oxaliplatin） |
| 36 |
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers |
Active, not recruiting |
NCT02349412
|
Phase 3 |
|
| 37 |
Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index |
Not yet recruiting |
NCT02576080
|
Phase 3 |
Imatinib |
| 38 |
Study of Romiplostim for Chemo-induced Thrombocytopenia in Adults Subjects With Gastrointestinal or Colorectal Cancer |
Not yet recruiting |
NCT03362177
|
Phase 3 |
|
| 39 |
IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer |
Suspended |
NCT00316745
|
Phase 3 |
Campto, Topotesin;TS-1;L-Plat;Isovorin;5-FU |
| 40 |
Effects of 3 Day Preoperative Immunonutrition in Well-nourished Patients With Gastrointestinal (GI) Cancer Undergoing Surgery |
Terminated |
NCT01023412
|
Phase 3 |
|
| 41 |
Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer |
Terminated |
NCT00387348
|
Phase 3 |
escitalopram oxalate;Placebo |
| 42 |
A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients |
Terminated |
NCT00254436
|
Phase 3 |
Procrit (epoetin alfa) |
| 43 |
Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients |
Terminated |
NCT00516269
|
Phase 3 |
Methylphenidate;Placebo |
| 44 |
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo |
Terminated |
NCT00332280
|
Phase 2, Phase 3 |
AMT2003 |
| 45 |
Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer |
Unknown status |
NCT00209651
|
Phase 2 |
Campto, Topotesin;TS-1 |
| 46 |
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer |
Unknown status |
NCT00019474
|
Phase 2 |
fluorouracil;hydroxyurea |
| 47 |
Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis |
Unknown status |
NCT00454519
|
Phase 2 |
|
| 48 |
Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) in Patients With Advanced Gastric Cancer |
Unknown status |
NCT01980407
|
Phase 2 |
S-1, leucovorin, oxaliplatin |
| 49 |
Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer |
Unknown status |
NCT00453323
|
Phase 2 |
Paclitaxel;Capecitabine |
| 50 |
Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Tumors |
Unknown status |
NCT00691691
|
Phase 2 |
|
Inferred drug relations via
UMLS
73
/
NDF-RT
51
:
|
